Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;3(8):100335.
doi: 10.1016/j.jtocrr.2022.100335. Epub 2022 May 20.

Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis

Christine M Bestvina  1 , Jennifer G Whisenant  2 , Valter Torri  3 , Alessio Cortellini  4 , Heather Wakelee  5 , Solange Peters  6 , Elisa Roca  7 , Alessandro De Toma  8 , Fred R Hirsch  9 , Hirva Mamdani  10 , Balazs Halmos  11 , Oscar Arrieta  12 , Anne-Cecile Metivier  13 , Mary J Fidler  14 , Jacobo Rogado  15 , Carolyn J Presley  16 , Celine Mascaux  17   18 , Carlo Genova  19   20 , Juan Bautista Blaquier  21 , Alfredo Addeo  22 , Giovanna Finocchiaro  23 , Hina Khan  24 , Julien Mazieres  25 , Floriana Morgillo  26 , Jair Bar  27 , Avinash Aujayeb  28 , Giannis Mountzios  29 , Vieri Scotti  30 , Federica Grosso  31 , Erica Geraedts  32 , Ardak N Zhumagaliyeva  33 , Leora Horn  2 , Marina Chiara Garassino  1 , Javier Baena  34 ; TERAVOLT study group
Affiliations

Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis

Christine M Bestvina et al. JTO Clin Res Rep. 2022 Aug.

Abstract

Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination.

Methods: A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model.

Results: We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15-0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33-1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients.

Conclusions: TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.

Keywords: COVID-19; Cancer; NSCLC; Registry; TERAVOLT; Thoracic.

PubMed Disclaimer

References

    1. Garassino M.C., Whisenant J.G., Huang L.C., et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914–922. - PMC - PubMed
    1. Whisenant J.G., Baena J., Cortellini A., et al. A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry. J Thorac Oncol. 2022;17:661–674. - PMC - PubMed
    1. World Health Organization Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1....
    1. Cao Y., Wang J., Jian F., et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657–663. - PMC - PubMed
    1. Maslo C., Friedland R., Toubkin M., Laubscher A., Akaloo T., Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves. JAMA. 2022;327:583–584. - PMC - PubMed